What this means
This study is testing whether one dose of ER-100 is safe for adults with glaucoma or a type of optic nerve damage. It is still recruiting, so no results are available yet.
Plain-English summary written by an AI model from the registry listing.
- Status
- Recruiting
- Who can join
- Ages 40–85
- Where
- 4 sites, including California, Massachusetts, New York
The science
- Registered title
- Evaluating ER-100 for Safety in People With Glaucoma or Non-Arteritic Anterior Ischemic Optic Neuropathy (Optic Nerve Conditions)
- Trial ID
- NCT07290244 ↗
- Phase
- PHASE 1
- Study type
- interventional
- Conditions
- Open Angle Glaucoma (OAG), NAION( Non-arteritic Anterior Ischemic Optic Neuropathy)
- What is tested
- ER-100 epigenetic therapy
- Sponsor
- Life Biosciences Inc.
- Ages
- 40 Years to 85 Years
- Dates
- First posted Dec 18, 2025 · updated May 19, 2026
Registry summary
The goal of this clinical trial is to evaluate the safety and tolerability of a single dose of ER-100 in adults with optic nerve conditions, specifically Open Angle Glaucoma (OAG) and Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION). The main questions it aims to answer are:
- Is ER-100 safe when given as a single dose to people with OAG or NAION
- What side effects may occur, if any, after taking ER-100?
Participants will:
- Receive a single dose of ER-100
- Undergo safety assessments including detailed eye examination and laboratory tests
- Provide body fluid samples (tears, saliva, feces, urine) to help researchers understand how the drug is processed and cleared from the body
- Complete questionnaires about their quality of life
- Be followed for up to 5 years to monitor long-term health and vision outcomes
Sites (4)
- Global Research Management, Inc., Glendale, California, United States
- Mass Eye and Ear, Boston, Massachusetts, United States
- Columbia University Irving Medical Center/Edward S. Harkness Eye Institute, New York, New York, United States
- Charleston Neuroscience Institute, Charleston, South Carolina, United States